Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD40


Brief Information

Name:Tumor necrosis factor receptor superfamily member 5
Target Synonym:Bp50,CD40 Antigens,CD40,B Cell Surface Antigen CD40,B-Cell Surface Antigen CD40,CDW40,CD40L Receptor,CD40 Molecule,Tumor Necrosis Factor Receptor Superfamily, Member 5,CD40 Molecule, TNF Receptor Superfamily Member 5,TNFRSF5,Tumor Necrosis Factor Receptor Superfamily Member 5,P50,CD40 Antigen,B Cell-Associated Molecule
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:25
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data

CD0-H525a-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that Human CD40, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD0-H525a) can bind to 293T cells overexpressing human CD40L. The concentration of Human CD40 is 0.03 μg/ml (Routinely tested).

TN5-H82F9-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that Biotinylated Human CD40, Fc,Avitag (Cat. No. TN5-H82F9) can bind to 293T cells overexpressing human CD40L. The concentration of Biotinylated Human CD40 is 0.1 μg/mL (Routinely tested).


Loaded Human CD40, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD0-H525a) on Protein A Biosensor, can bind Human CD40 Ligand, His,Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H52Db) with an affinity constant of 0.911 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).


Loaded Rhesus macaque CD40, Fc Tag (Cat. No. CD0-C5259) on Protein A Biosensor, can bind Human CD40 Ligand, His,Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H52Db) with an affinity constant of 0.829 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name



CD40 is also known as TNFRSF5, Bp50, CDW40, MGC9013, TNFRSF5 and  p50, is a member of the TNF receptor superfamily which are single transmembrane-spanning glycoproteins, and plays an essential role in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. CD40 is a costimulatory protein found on antigen presenting cells and is required for their activation. The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects. CD40 contains 4 cysteine-rich repeats in the extracellular domain, and is expressed in B cells, dendritic cells, macrophages, endothelial cells, and several tumor cell lines. The extracellular domain has the cysteinerich repeat regions, which are characteristic for many of the receptors of the TNF superfamily. Interaction of CD40 with its ligand, CD40L, leads to aggregation of CD40 molecules,which in turn interact with cytoplasmic components to initiate signaling pathways. Early studies on the CD40-CD40L system revealed its role in humoral immunity. Defects in CD40 result in hyper-IgM immunodeficiency type 3 (HIGM3), an autosomal recessive disorder characterized by an inability of B cells to undergo isotype switching, as well as an inability to mount an antibody-specific immune response, and a lack of germinal center formation.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
FFP-102 5-D12; PG-102 Phase 2 Clinical Pangenetics Arthritis, Psoriatic; Crohn Disease Details
SHR-1704 SHR-1704 Phase 1 Clinical Hematologic Diseases Details
CD40.HIVRI.Env Vaccine Phase 1 Clinical HIV Infections Details
BI-655064 BI-655064 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Purpura, Thrombocytopenic, Idiopathic; Arthritis, Rheumatoid; Lupus Nephritis Details
FFP-104 FFP-104 Phase 2 Clinical Ff Pharma Liver Cirrhosis, Biliary; Crohn Disease Details
2141-V11 2141-V11 Phase 1 Clinical Darell Bigner Ganglioglioma Details
Bleselumab 4D-11; ASKP-1240 Phase 2 Clinical Kyowa Hakko Kogyo Rejection of renal transplantation; Rejection of organ transplantation; Glomerulosclerosis, Focal Segmental; Psoriasis Details
SEA-CD40 SEA-CD40 Phase 2 Clinical Seattle Genetics Lymphoma, B-Cell; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Neoplasms, Squamous Cell; Pancreatic Neoplasms; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Autologous IL2 and CD40 ligand-expressing tumor cells (Baylor College of Medicine) Phase 1 Clinical Baylor College Of Medicine Leukemia, Lymphocytic, Chronic, B-Cell Details
Ravagalimab ABBV-323; PR-1629977 Phase 2 Clinical Abbvie Inc Colitis, Ulcerative Details
Anti-CD40 ChiLob7/4 (BioNTech) Phase 2 Clinical Biontech Se Head and Neck Neoplasms; Pancreatic Neoplasms Details
Mitazalimab ADC-1013; JNJ-7107; JNJ-64457107 Phase 2 Clinical Alligator Bioscience Solid tumours; Carcinoma, Pancreatic Ductal Details
CD40L-GVAX GM.CD40L; CD40L-GVAX; GM-CSF/CD40L; hCD40L/hGM-CSF Phase 2 Clinical University Of South Florida Myelodysplastic Syndromes; Lung Neoplasms; Melanoma Details
MEDI-5083 MEDI-5083 Phase 1 Clinical Astrazeneca Plc, Medimmune Solid tumours Details
RO-7300490 RO-7300490; RG-6189 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours Details
BSI-038 BSI-038 Phase 1 Clinical Boaoxin Biotechnology(Nanjing) Co Ltd Solid tumours Details
CDX-1140 CDX-1140 Phase 2 Clinical Celldex Therapeutics Lymphoma, Follicular; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Waldenstrom Macroglobulinemia; Colorectal Neoplasms; Peritoneal Neoplasms; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Solid tumours; Urinary Bladder Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Lymphoma, B-Cell; Head and Neck Neoplasms; Ovarian Neoplasms; Liver Neoplasms; Lymphoma, B-Cell, Marginal Zone Details
LVGN-7409 LVGN7409; LVGN-7409 Phase 1 Clinical Lyvgen Biopharma(HK)Ltd Neoplasms Details
SL-172154 SL-172154 Phase 1 Clinical Shattuck Labs Inc Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms Details
MP-0317 MP-0317 Phase 1 Clinical Molecular Partners Ag Solid tumours; Neoplasms Details
YH-003 YH-003; YH003 Phase 2 Clinical Eucure Pharmaceutical Technology (Beijing) Co Ltd Solid tumours; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma Details
Tecaginlimab BNT-312; GEN-1042 Phase 2 Clinical Genmab Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma Details
KPL-404 KPL-404 Phase 2 Clinical Kiniksa Pharmaceuticals Ltd Arthritis, Rheumatoid Details
Sotigalimab APX-005; APX-005M; EPI-0050 Phase 2 Clinical Epitomics Head and Neck Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Microsatellite Instability; Sarcoma; Brain Neoplasms; Glioma; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Giloralimab ABBV-927 Phase 2 Clinical Abbvie Inc Head and Neck Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
NJA-730 NJA-730; NJA-730a; NJA-730b Phase 1 Clinical Napajen Pharma Graft vs Host Disease; Autoimmune Diseases of the Nervous System Details
Iscalimab CFZ-533; NVP-CFZ533; OM11-62-MF Phase 2 Clinical Novartis Pharma Ag Rejection of renal transplantation; Myasthenia Gravis; Diabetes Mellitus, Type 1; Rejection of liver transplantation; Arthritis, Rheumatoid; Sjogren's Syndrome; Lupus Nephritis; Lupus Erythematosus, Systemic; Graves Disease; Sjogren-Larsson Syndrome; Hidradenitis Suppurativa Details
TQB-2916 TQB2916; TQB-2916 Phase 1 Clinical Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group Neoplasms Details
MIL-97 MIL-97 Phase 1 Clinical Beijing Mabworks Biotech Co Ltd Solid tumours Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message